Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Estimates By $0.01 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.01, Zacks reports. The company had revenue of $207.00 million during the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%.

Ultragenyx Pharmaceutical Stock Down 1.5%

NASDAQ:RARE traded down $0.36 during mid-day trading on Thursday, hitting $23.52. 1,883,184 shares of the stock traded hands, compared to its average volume of 2,618,307. The business’s 50-day moving average price is $27.49 and its 200 day moving average price is $29.83. The company has a market cap of $2.27 billion, a PE ratio of -3.96 and a beta of 0.16. Ultragenyx Pharmaceutical has a 12-month low of $18.41 and a 12-month high of $46.27.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Q4 results edged past expectations: GAAP EPS of ($1.29) vs. consensus ($1.30) and revenue of $207M vs. $199.6M consensus — a sign the commercial business is growing and beat estimates. Quarterly Press Release
• Positive Sentiment: Full‑year 2025 revenue of $673M with product splits: Crysvita $481M and Dojolvi $96M — underscores recurring commercial revenue that supports medium‑term top‑line expectations. Full-Year Results
• Negative Sentiment: A securities class action has been filed alleging material misstatements/omissions (class period Aug 3, 2023–Dec 26, 2025); this formal filing is the primary legal driver weighing on the stock. Kessler Topaz Filing
• Negative Sentiment: Multiple law firms (e.g., Rosen, Portnoy, Bronstein, Levi & Korsinsky, Faruqi) are actively soliciting lead‑plaintiff roles and filing notices — amplifying media coverage and potential litigation costs/distraction for management. Rosen Law Notice
• Negative Sentiment: Multiple investor alerts and deadline reminders (lead‑plaintiff deadline April 6, 2026) from ClaimsFiler and other services keep the litigation visible to retail and institutional holders, sustaining near‑term selling pressure. ClaimsFiler Reminder

Wall Street Analysts Forecast Growth

RARE has been the subject of several research reports. Wells Fargo & Company reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, December 30th. Jefferies Financial Group decreased their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday, December 30th. Barclays lowered their price objective on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. TD Cowen cut their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Leerink Partners lowered their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Sixteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $72.29.

Insider Buying and Selling

In other news, CFO Howard Horn sold 3,081 shares of the business’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total transaction of $112,086.78. Following the completion of the transaction, the chief financial officer directly owned 95,146 shares in the company, valued at $3,461,411.48. The trade was a 3.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 6,227 shares of company stock valued at $187,126. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in RARE. Headlands Technologies LLC raised its position in shares of Ultragenyx Pharmaceutical by 638.3% during the 2nd quarter. Headlands Technologies LLC now owns 11,983 shares of the biopharmaceutical company’s stock valued at $436,000 after buying an additional 10,360 shares in the last quarter. E Fund Management Co. Ltd. grew its position in Ultragenyx Pharmaceutical by 9.1% in the second quarter. E Fund Management Co. Ltd. now owns 9,052 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 752 shares in the last quarter. Tidal Investments LLC increased its stake in Ultragenyx Pharmaceutical by 4.7% in the second quarter. Tidal Investments LLC now owns 12,591 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 564 shares during the last quarter. Brevan Howard Capital Management LP purchased a new stake in Ultragenyx Pharmaceutical during the second quarter valued at about $297,000. Finally, American Century Companies Inc. purchased a new stake in Ultragenyx Pharmaceutical during the second quarter valued at about $366,000. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.